Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Potential Metabolites with Diagnostic Value in Plasma for Angioimmunoblastic T-Cell Lymphoma By LC-MS Based Untargeted Metabonomics Study

Haiyan Yang, Tao Lei, Cong Li, Haifeng Yu, Zhongjian Chen

Blood (2019) 134 (Supplement_1): 5234.

https://doi.org/10.1182/blood-2019-129897

Published: 2019

Journal Articles

Pre-Treatment with Bendamustine Does Not Affect Stem Cell Mobilization in Patients with Indolent Non-Hodgkin Lymphomas: A Multicenter Study on Behalf of the Fondazione Italiana Linfomi

Michele Merli, MD, Stefano Luminari, MD, Lucia Farina, Federica Cocito, MD, Irene Defrancesco, MD, Guido Gini, MD, Annalisa Arcari, MD, Greta Scapinello, MD, Massimo Gentile, MD, Maria Goldaniga, MD, Giacomo Loseto, MD, Emanuele Cencini, MD, Antonino Greco, MD, Andrea Ferrario, MD, Benedetta Bianchi, MD, Francesca Gaia Rossi, MD, Silvia Bolis, MD, Francesco Passamonti, MD, Luca Arcaini, MD

Blood (2018) 132 (Supplement 1): 2066.

https://doi.org/10.1182/blood-2018-99-113536

Published: 2018

Journal Articles

Structure-Function Relationships of Novel Benzimidazole-Based Inhibitors of the Isoprenoid Biosynthetic Pathway in Myeloma Cells

Michelle L. Varney, MS, Nazmul H. Bhuiyan, B.S., David F. Wiemer, PhD, Sarah A. Holstein, MD PhD

Blood (2017) 130 (Supplement 1): 3345.

https://doi.org/10.1182/blood.V130.Suppl_1.3345.3345

Published: 2017

Journal Articles

Prospective Analysis of Cytomegalovirus Reactivation and the Immune State of Low-Grade B-Cell Lymphoma Patients Treated with Bendamustine

Noriko Isono, MD, Yoichi Imai, MD PhD, Chihiro Asano, MD, Michihiko Masuda, MD PhD, Shigeru Hoshino, MD PhD, Keiichi Moriya, MD PhD, Hideto Tamura, MD PhD, Koiti Inokuchi, MD PhD, Shigeki Ito, MD, PhD, Yoji Ishida, MD, PhD, Toshiko Motoji, MD PhD, Junji Tanaka, MD PhD

Blood (2014) 124 (21): 4411.

https://doi.org/10.1182/blood.V124.21.4411.4411

Published: 2014

Journal Articles

Bendamustine Is Not Associated With An Increase In Infections – Systematic Review and Meta-Analysis Of Randomized Controlled Trials

Anat Gafter-Gvili, MD, Ronit Gurion, MD, Pia Raanani, MD, Ofer Shpilberg, MD, MPH, Liat Vidal, MD MSc

Blood (2013) 122 (21): 5125.

https://doi.org/10.1182/blood.V122.21.5125.5125

Published: 2013

Journal Articles

Bendamustine, Bortezomib and Dexamethasone (BVD): A Combination With a Substantial Activity and a Manageable Toxicity In Patients With Relapsed-Refractory Multiple Myeloma (MM)

Blood (2013) 122 (21): 1974.

https://doi.org/10.1182/blood.V122.21.1974.1974

Published: 2013

Journal Articles

Bendamustine, Bortezomib and Dexamethasone (BBD) As First-Line Treatment Of Patients (Pts) With Multiple Myeloma Who Are Not Candidates For High Dose Chemotherapy

Jesus Berdeja, MD, Michael Savona, MD, Luis Chu, MD, James Essell, MD, Patrick Murphy, MD, Todd Bauer, MD, Eric Raefsky, MD, Ralph V. Boccia, MD, Ian Flinn, MD, PhD

Blood (2013) 122 (21): 3193.

https://doi.org/10.1182/blood.V122.21.3193.3193

Published: 2013

Journal Articles

Very High Rates of Clinical and Cytogenetic Response with the Combination of the Histone Deacetylase Inhibitor Pracinostat (SB939) and 5-Azacitidine in High-Risk Myelodysplastic Syndrome

Alfonso Quintás-Cardama, M.D., Hagop M. Kantarjian, MD, Farhad Ravandi, Cielo Foudray, Naveen Pemmaraju, Tapan M. Kadia, M.D., Gautam Borthakur, M.D., Naval G. Daver, MD, Stefan Faderl, MD, Elias Jabbour, Jorge E. Cortes, MD, Guillermo Garcia-Manero, MD

Blood (2012) 120 (21): 3821.

https://doi.org/10.1182/blood.V120.21.3821.3821

Published: 2012

Journal Articles

Bendamustine, Bortezomib and Dexamethasone (BBD) As First-Line Treatment of Patients with Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy: Toxicity Comparison of Two Dose Schedules

Jesus G. Berdeja, MD, Michael R. Savona, MD, FACP, James Essell, MD, Patrick Murphy, MD, Luis Chu, MD, Ralph V. Boccia, MD, Edward Arrowsmith, MD, MPH, Ian W. Flinn, MD, PhD

Blood (2012) 120 (21): 4047.

https://doi.org/10.1182/blood.V120.21.4047.4047

Published: 2012

Journal Articles

Safety, Tolerability and Activity of Ofatumumab, Bendamustine and Dexamethasone Combination As First-Line Treatment of Mantle-Cell Lymphoma in the Elderly: A Multicenter Study

Blood (2011) 118 (21): 1647.

https://doi.org/10.1182/blood.V118.21.1647.1647

Published: 2011

Journal Articles

Inhibition of IRAK1 As a Novel Therapeutic Strategy in Acute Myeloid Leukemia and Myelodysplastic Syndrome

Garrett Rhyasen, BSc, Lyndsey Bolanos, BSc, Jing Fang, MD/PhD, Carmen Rigolino, BSc, Agostino Cortelezzi, MD, Esther Natalie Oliva, MD, Mariella Cuzzola, MD, Daniel T Starczynowski, PhD

Blood (2011) 118 (21): 612.

https://doi.org/10.1182/blood.V118.21.612.612

Published: 2011

Journal Articles

An Open-Label Phase I Pharmacokinetic Study of [ 14 c] Bendamustine in Patients with Relapsed or Refractory Malignancy

Anne-Charlotte Dubbelman, MSc, Hilde Rosing, PhD, Mona Darwish, PhD, Denise D'Andrea, MD, Mary Bond, MS, MBA, Edward T. Hellriegel, PhD, Jos H. Beijnen, PharmD, PhD, Jan H. M. Schellens, MD, PhD

Blood (2011) 118 (21): 2476.

https://doi.org/10.1182/blood.V118.21.2476.2476

Published: 2011

Journal Articles

Therapy with the Histone Deacetylase Inhibitor Sb939 for Patients with Myelofibrosis,

Alfonso Quintás-Cardama, MD, Hagop M Kantarjian, Gautam Borthakur, Zeev Estrov, Jorge E. Cortes, Srdan Verstovsek, MD, PhD

Blood (2011) 118 (21): 3863.

https://doi.org/10.1182/blood.V118.21.3863.3863

Published: 2011

Journal Articles

A Phase II Trial of Combined Bendamustine, Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma (MM) Patients Who Are Not Candidates for High-Dose Chemotherapy: Results of a Planned Interim Safety Analysis

Jesus G. Berdeja, MD, Daniel R. Couriel, MD, Patrick Murphy, MD, Ralph V. Boccia, MD, Victor Priego, MD, John D. Hainsworth, MD, Inés M. Macias-Pérez, PhD, Ian W. Flinn, MD, PhD

Blood (2011) 118 (21): 2943.

https://doi.org/10.1182/blood.V118.21.2943.2943

Published: 2011

Journal Articles

Bortezomib Induced BRCAness Sensitizes Multiple Myeloma Cells to PARP Inhibitors

Paola Neri, MD, PhD, Li Ren, PhD, Kathy Gratton, Erin Stebner, Carolyn J Owen, MD, FRCPC, Peter Duggan, MD, FRCPC, Adnan Mansoor, MD, FCPS, FRCP(C), FCAP, Douglas A. Stewart, MD, FRCP, Nizar J Bahlis, MD

Blood (2010) 116 (21): 789.

https://doi.org/10.1182/blood.V116.21.789.789

Published: 2010

Journal Articles

Combined Bendamustine, Prednisolone and Lenalidomide (RBP) In Refractory or Relapsed Multiple Myeloma. First Results of a Phase I Clinical Trial

Wolfram Pönisch, Simone Heyn, Ina Wagner, Martin Mohren, MD, Franz-Albert Hoffmann, Frank Schüler, Marion Schmalfeld, Haifa K. Al-Ali, Nadja Jäkel, Dietger W Niederwieser, MD

Blood (2010) 116 (21): 1971.

https://doi.org/10.1182/blood.V116.21.1971.1971

Published: 2010

Journal Articles

An Open-Label Phase 1/2 Trial of Bendamustine Combined with Bortezomib for Patients with Relapsed/Refractory Multiple Myeloma

James R. Berenson, MD, Ori Yellin, MD, Alberto Bessudo, MD, Ralph Boccia, MD, Donald S. Gravenor, MD, Stephen J. Noga, MD, PhD, Robert S Siegel, MD, Regina A. Swift, RN, Michael D Ehrman, MS, Debra Bensen-Kennedy, MD

Blood (2010) 116 (21): 3057.

https://doi.org/10.1182/blood.V116.21.3057.3057

Published: 2010

Journal Articles

The Novel 2 nd Generation Small Molecule MEK Inhibitor, AZD-6244, Induces Cell Death in Lymphoma Cells Lines, Primary Cells, and in a Human Lymphoma Xenograft Model.

Savita Bhalla, PhD, Ron Gartenhaus, MD, Bojie Dai, PhD, Sheila Prachand, Arindam Mukherjee, Rebecca L Elstrom, MD, Leo I. Gordon, MD, Andrew M. Evens, DO, MSc

Blood (2009) 114 (22): 285.

https://doi.org/10.1182/blood.V114.22.285.285

Published: 2009

Journal Articles

Nocodazole Induces Multiple Myeloma Cell Death and Reduces Tumor Growth through Sequential Microtubular Network Damage and C-Jun N-Terminal Kinase-Mediated Bcl-2 Phosphorylation.

Rentian Feng, PhD, Huihui Ma, Noriyoshi Kurihara, PhD, DDS, Shirong Li, PhD, Judy A Ziegler, Markus Y Mapara, MD, PhD, G. David Roodman, MD, PhD, Suzanne Lentzsch, MD, PhD

Blood (2009) 114 (22): 296.

https://doi.org/10.1182/blood.V114.22.296.296

Published: 2009

Journal Articles

Casein Kinase CK2 Inhibition Results in Tumor Suppression.

Hanan Mohammad, B.S., Daniel j Lindner, M.D., Ph.D., Michael Kalafatis, PhD

Blood (2009) 114 (22): 5052.

https://doi.org/10.1182/blood.V114.22.5052.5052

Published: 2009

NARROW

Potential Metabolites with Diagnostic Value in Plasma for Angioimmunoblastic T-Cell Lymphoma By LC-MS Based Untargeted Metabonomics Study

Pre-Treatment with Bendamustine Does Not Affect Stem Cell Mobilization in Patients with Indolent Non-Hodgkin Lymphomas: A Multicenter Study on Behalf of the Fondazione Italiana Linfomi

Structure-Function Relationships of Novel Benzimidazole-Based Inhibitors of the Isoprenoid Biosynthetic Pathway in Myeloma Cells

Prospective Analysis of Cytomegalovirus Reactivation and the Immune State of Low-Grade B-Cell Lymphoma Patients Treated with Bendamustine

Bendamustine Is Not Associated With An Increase In Infections – Systematic Review and Meta-Analysis Of Randomized Controlled Trials

Bendamustine, Bortezomib and Dexamethasone (BVD): A Combination With a Substantial Activity and a Manageable Toxicity In Patients With Relapsed-Refractory Multiple Myeloma (MM)

Bendamustine, Bortezomib and Dexamethasone (BBD) As First-Line Treatment Of Patients (Pts) With Multiple Myeloma Who Are Not Candidates For High Dose Chemotherapy

Very High Rates of Clinical and Cytogenetic Response with the Combination of the Histone Deacetylase Inhibitor Pracinostat (SB939) and 5-Azacitidine in High-Risk Myelodysplastic Syndrome

Bendamustine, Bortezomib and Dexamethasone (BBD) As First-Line Treatment of Patients with Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy: Toxicity Comparison of Two Dose Schedules

Safety, Tolerability and Activity of Ofatumumab, Bendamustine and Dexamethasone Combination As First-Line Treatment of Mantle-Cell Lymphoma in the Elderly: A Multicenter Study

Inhibition of IRAK1 As a Novel Therapeutic Strategy in Acute Myeloid Leukemia and Myelodysplastic Syndrome

An Open-Label Phase I Pharmacokinetic Study of [ 14 c] Bendamustine in Patients with Relapsed or Refractory Malignancy

Therapy with the Histone Deacetylase Inhibitor Sb939 for Patients with Myelofibrosis,

A Phase II Trial of Combined Bendamustine, Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma (MM) Patients Who Are Not Candidates for High-Dose Chemotherapy: Results of a Planned Interim Safety Analysis

Bortezomib Induced BRCAness Sensitizes Multiple Myeloma Cells to PARP Inhibitors

Combined Bendamustine, Prednisolone and Lenalidomide (RBP) In Refractory or Relapsed Multiple Myeloma. First Results of a Phase I Clinical Trial

An Open-Label Phase 1/2 Trial of Bendamustine Combined with Bortezomib for Patients with Relapsed/Refractory Multiple Myeloma

The Novel 2 nd Generation Small Molecule MEK Inhibitor, AZD-6244, Induces Cell Death in Lymphoma Cells Lines, Primary Cells, and in a Human Lymphoma Xenograft Model.

Nocodazole Induces Multiple Myeloma Cell Death and Reduces Tumor Growth through Sequential Microtubular Network Damage and C-Jun N-Terminal Kinase-Mediated Bcl-2 Phosphorylation.

Casein Kinase CK2 Inhibition Results in Tumor Suppression.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only